To determine the efficacy and toxicity of irinotecan combined with carboplatin, we conducted a phase II trial. Eligibility criteria were: chemotherapy-naïve, small-cell lung cancer (SCLC), good performance status (PS: 0-2), age
Download full-text PDF
Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361403 PMC http://dx.doi.org/10.1038/sj.bjc.6603079 DOI Listing Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!